

IAP4 Rec'd PCT/PTO 04 JAN 2006  
PCT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 21415-0019

Applicant(s): Jonathan BAELL et al.

Confirmation No.: 3533

Appl. No.: 10/540,390

Examiner: Unassigned

Filing Date: June 23, 2005

Art Unit: Unassigned

Title: PEPTIDE AND THERAPEUTIC USES THEREOF

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.56 and 37 CFR §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

**TIMING/FEE**

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

RELEVANCE


Documents A01-A03 came to the Applicants' attention during a search of the corresponding international application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: January 4, 2006

HELLER EHRMAN LLP  
1717 Rhode Island Avenue, NW  
Washington, DC 20036  
Telephone: (202) 912-2142  
Facsimile: (202) 912-2020

By 

Paul M. Booth  
Attorney for Applicants  
Registration No. 40,244  
Customer No. 26633

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	7
-------	---	----	---

Application Number	10/540,390
Filing Date	June 23, 2005
First Named Inventor	BAELL et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	21415-0019

[illegible][illegible]

Date Considered

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)



Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/540,390
		Filing Date	June 23, 2005
		First Named Inventor	BAELL et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 2 of 7	Attorney Docket Number	21415-0019	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A04	JERRY M. ADAMS et al., "Apoptosomes: engines for caspase activation", Current Opinion in Cell Biology, 2002, pp. 715-720	
	A05	JERRY M. ADAMS et al., "Oncogene Co-operation in Leukaemogenesis", Cancer Surveys, 1992, pp. 119-141, Vol. 15	
	A06	JERRY M. ADAMS et al., "The Bcl-2 Protein Family: Arbiters of Cell Survival", Science, Aug. 28, 1998, pp. 1322-1326, Vol. 281	
	A07	J.M. ADAMS et al., "Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector", Oncogene, 1999, pp. 5268-5277, Vol. 18	
	A08	JERRY M. ADAMS et al., "Life-or-death decisions by the Bcl-2 protein family", Trends in Biochemical Sciences, 2001, pp. 61-66, Vol. 26	
	A09	BRUNO ANTONSSON et al., "Bax Is Present as a High Molecular Weight Oligomer/Complex in the Mitochondrial Membrane of Apoptotic Cells", The Journal of Biological Chemistry, 2001, pp. 11615-11623, Vol. 276, No. 15	
	A10	AVI ASHKENZAI et al., "Death Receptors: Signaling and Modulation", Science, 1998, pp. 1305-1308, Vol. 281	
	A11	PHILIPPE BOUILLET et al., "Proapoptotic Bcl-2 Relative Bim Required for Certain Apoptotic Responses, Leukocyte Homeostasis, and to Preclude Autoimmunity", Science, 1999, pp. 1735-1738, Vol. 286	
	A12	PHILIPPE BOUILLET et al., "Degenerative Disorders Caused by Bcl-2 Deficiency Prevented by Loss of Its BH3-Only Antagonist Bim", Developmental Cell, 2001, pp. 645-653, Vol. 1	
	A13	LEO BRADY et al., "Reflections on a peptide", Nature, 1994, pp. 692-693, Vol. 368	
	A14	J. MARTIN BROWN et al., "Apoptosis, p53, and Tumor Cell Sensitivity to Anticancer Agents", Cancer Research, 1999, pp. 1391-1399, Vol. 59	
	A15	R. BURGI et al., "Folding study of an Aib-rich peptide in DMSO by molecular dynamics simulations", Journal of Peptide Research, 2001, pp. 107-118, Vol. 57	
	A16	FANGLI CHEN et al., "Translocation of C. elegans CED-4 to Nuclear Membranes During Programmed Cell Death", Science, 2000, pp. 1485-1489, Vol. 287	
	A17	EMILY H.-Y.A. CHENG et al., "BCL-2, BCL-X <sub>L</sub> Sequester BH3 Domain-Only Molecules Preventing BAX- and BAK-Mediated Mitochondrial Apoptosis", Molecular Cell, 2001, pp. 705-711, Vol. 8	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Unique citation designation number.<sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/540,390	
			Filing Date	June 23, 2005	
			First Named Inventor	BAELL et al.	
			Group Art Unit	Unassigned	
			Examiner Name	Unassigned	
Sheet	3	of	7	Attorney Docket Number	21415-0019

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A18	ARUL M. CHINNAIYAN et al., Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death", Science, 1997, pp. 1122-1126, Vol. 275	
	A19	MICHAEL L. CLEARY et al., "Cloning and Structural Analysis of cDNAs for bcl-2 and a Hybrid bcl-2/Immunoglobulin Transcript Resulting from the t(14;18) Translocation", Cell, 1986, pp. 19-28, Vol. 47	
	A20	BARBARA CONRADT et al., "The C. elegans Protein EGL-1 Is Required for Programmed Cell Death and Interacts with the Bcl-2-like Protein CED-9", 1998, Cell, pp. 519-529, Vol. 93	
	A21	S. CONUS et al., "Failure of Bcl-2 family members to interact with Apaf-1 in normal and apoptotic cells", Cell and Death and Differentiation, 2000, pp. 947-954, Vol. 7	
	A22	SUZANNE CORY et al., "The BCL2 Family: Regulators of the Cellular Life-or-Death Switch", Nature Reviews Cancer, 2002, pp. 647-656, Vol. 2	
	A23	SOLANGE DESAGHER et al., "Bid-induced Conformational Change of Bax Is Responsible for Mitochondrial Cytochrome c Release during Apoptosis", The Journal of Biology, 1999, pp. 891-901, Vol. 144	
	A24	CHUNYING DU et al., "Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition", Cell, 2000, pp. 33-42, Vol. 102	
	A25	ROBERT ESKES et al., "Bid Induces the Oligomerization and Insertion of Bax into the Outer Mitochondrial Membrane", Molecular and Cellular Biology, 2000, pp. 929-935, Vol. 20, No. 3	
	A26	DAVID E. FISHER, "Apoptosis in Cancer Therapy: Crossing the Threshold", Cell, 1994, pp. 539-542, Vol. 78	
	A27	JIA-WEN HAN et al., "Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals", PNAS, 2001, pp. 11318-11323, Vol. 98, No. 20	
	A28	MISAKO HARAGUCHI et al., "Apoptotic Protease Activating Factor 1 (Apaf-1)-independent Cell Death Suppression by Bcl-2", J. Exp. Med., 2000, J. Exp. Med., 2000, pp. 1709-1720, Vol. 191, No. 10	
	A29	DAVID C. S. HUANG et al., "BH3-only proteins-essential initiators of apoptotic cell death", Cell, 2000, pp. 839-842	
	A30	BRADFORD A. JAMESON et al. "A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis", 1994, pp. 744-746, Vol. 368	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/540,390
		Filing Date	June 23, 2005
		First Named Inventor	BAELL et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 4 of 7	Attorney Docket Number	21415-0019	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A31	JULIANE M. JURGENSMEIER et al., "Bax directly induces release of cytochrome c from isolated mitochondria", Proceedings of the National Academy of Sciences of the United States of America, 1998, pp. 4997-5002, Vol. 95	
	A32	SHINJI KAMADA et al., "Bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine", 1995, Cancer Research, pp. 354-359, Vol. 55	
	A33	RUTH M. KLUCK et al., "The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis", Science, 1997, pp. 1132-1136, Vol. 275	
	A34	SJ KORSMEYER et al., "Pro5 apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c", Cell Death and Differentiation, 2000, pp. 1166-1173, Vol. 7	
	A35	D.P. LANE, "p53, guardian of the genome", Nature, 1992, pp. 15-16, Vol. 358	
	A36	TSVEE LAPIDOT et al., "Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis", Journal of Molecular Medicine, 1997, pp. 664-673, Vol. 75	
	A37	PENG LI et al., "Cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade", Cell, 1997, pp. 479-489, 1997, Vol. 91	
	A38	SCOTT W. LOWE et al., "p53 is required for radiation-induced apoptosis in mouse thymocytes", Nature, 1993, pp. 847-849, Vol. 362	
	A39	VANESSA S. MARSDEN et al., "Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome", Nature, 2002, pp. 634-620, Vol. 419	
	A40	VALERY MIKHAILOV et al., "Bcl-2 prevents bax oligomerization in the mitochondrial outer membrane", Journal of Biological Chemistry, 2001, pp. 18361-18374, Vol. 276(21)	
	A41	KOJJI MORIISHI et al., "Bcl-2 family members do not inhibit apoptosis by binding the caspase-activator Apaf-1", Proceedings of the National Academy of Sciences of the United States of America, 1999, pp. 9683-9688, Vol. 96	
	A42	NOBORU MOTOYAMA et al., "Massive cell death of immature hematopoietic cells and neurons in Bcl-x deficient mice", Science, 1995, pp. 1506-1510, Vol. 267	
	A43	NOBORU MOTOYAMA et al., "Bcl-x prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation", Journal of Experimental Medicine, 1999, pp. 1691-1698, Vol. 189 (11)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/540,390
		Filing Date	June 23, 2005
		First Named Inventor	BAELL et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 5 of 7	Attorney Docket Number	21415-0040	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A44	KATSUNORI NAKANO et al., "PUMA, a novel proapoptotic gene, is induced by p53", Molecular Cell, 2001, pp. 683-694, Vol. 7	
	A45	KEIKO NAKAYAMA et al., "Targeted disruption of Bcl-2ap in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia", Proceedings of the National Academy of Sciences of the United States of America, 1994, pp. 3700-3704, Vol. 91	
	A46	ERI ODA et al., "Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis", Science, 2000, pp. 1053-1058, Vol. 288 (5468)	
	A47	JAY PARRISH et al., "Demonstration of the in vivo interaction of key cell death regulators by structure-based design of second-site suppressors", Proceedings of the National Academy of Sciences of the USA, 2000, pp. 11916-11921, Vol. 97 (22)	
	A48	ANDERW M. PETROS et al., "Rationale for BclxL/Bad peptide complex formation from structure, mutagenesis and biophysical studies", Protein Science, 2000, pp. 2528-2534, Vol. 9	
	A49	CRISTIN G. PRINT et al., "Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant", Proceedings of the National Academy of Sciences of the United States of America, 1998, pp. 12424-12431, Vol. 95	
	A50	HAMSA PUTHALAKATH et al., "The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex", 1999, Molecular Cell, pp. 287-296, Vol. 3	
	A51	HAMSA PUTHALAKATH et al., "Bmf: a pro-apoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis", Science, 2001, pp. 1829-1832, Vol. 293	
	A52	ANDREA J. ROSS et al., "Testicular degeneration in Bclw-deficient mice", Nature Genetics, 1998, pp. 251-256	
	A53	MICHAEL SATTler et al., "Structure of Bcl-xL/Bak peptide complex: recognition between regulators of apoptosis", Science, 1997, 983-986, Vol. 275 (5302)	
	A54	MONA S. SPECTOR et al., "Interaction between the C. elegans cell-death regulators CED-9 and CED-4", Nature, 1997, pp. 653-656, Vol. 385 (6617)	
	A55	ANDREAS STRASSER et al., "Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and Bcl-2", Nature, 1990, pp. 331-333, Vol. 384	
	A56	ANDREAS STRASSER et al., "DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2", Cell, 1994, pp. 329-339, Vol. 79	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/540,390	
			Filing Date	June 23, 2005	
			First Named Inventor	BAELL et al.	
			Group Art Unit	Unassigned	
			Examiner Name	Unassigned	
Sheet	6	of	7	Attorney Docket Number	21415-0019

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A57	ANDREAS STRASSER et al., Progenitor tumours from Elx-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal 20 developmental differences in cell survival", EMBO, 1996, pp. 3823-3834, Vol. 15, No. 15	
	A58	ANDREAS STRASSER et al., "The role of the Bcl-2/CED-9 gene family in cancer and general implications of defects in cell death control for tumorigenesis and resistance to chemotherapy", Biochimica et Biophysica Acta, 1997, pp. F151-F178, Vol. 1333	
	A59	ANDREAS STRASSER et al., "Apoptosis signaling", Annual Review of Biochemistry, 2000, pp. 217-245, Vol. 69	
	A60	MOTOSHI SUZUKI et al., "Structure of Bax: coregulation of dimer formation and intracellular localization" Cell, 2000, pp. 645-654, Vol. 103	
	A61	CRAIG B. THOMPSON, "Apoptosis in the pathogenesis and treatment of disease, "Science, 1995, pp. 1456-1462, Vol. 267	
	A62	NANCY A. THOMBERRY et al., "Caspases: enemies within", Science, 1998, pp. 1312-1316, Vol. 281	
	A63	Y. TSUJIMOTO et al., "Involvement of the Bcl-2 gene in human follicular lymphoma", Science, 1985, pp. 1440-1443, Vol. 228	
	A64	DAVID L. VAUX et al., "Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells", Nature, 1998, pp. 440-442, Vol. 335	
	A65	DEBORAH J. VEIS et al., "Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair", Cell, 1993, pp. 229-240, Vol. 75	
	A66	ANNE M. VERHAGEN et al., "Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing inhibitor of apoptosis (IAP) proteins", Cell, 2000, pp. 43-53, vol. 102	
	A67	KAREN H. VOUSDEN, "p53: death star, "Cell, 2000, pp. 691-694, Vol. 103	
	A68	KUN WANG et al., "BID: a novel BH3 domain-only death agonist", Genes and Development, 1996, pp. 2859-2869, Vol. 10	
	A69	MICHAEL C. WEI et al., "Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death", Science, 2001, pp. 727-730. Vol. 292	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Unique citation designation number. <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign (+) inside this box ☐ PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/540,390		
		Filing Date	June 23, 2005		
		First Named Inventor	BAELL et al.		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	7	of	7	Attorney Docket Number	21415-0019

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A70	DAYANG WU et al., "Interaction and regulation of subcellular localization of CED-4 and CED-9", Science, 1997, pp. 1126-1129, Vol. 275	
	A71	JEN TSI YANG et al., "Calculation of protein conformation from circular dichroism", Methods Enzymol., 1986, pp. 208-2,69, Vol. 130	
	A72	JIE YANG et al., "Prevention of apoptosis by Bcl-2-release of cytochrome c from mitochondria blocked", Science, 1997, pp. 1129-1132, Vol. 275	
	A73	XIAOLU YANG et al., "Essential role of CED-4 oligomerization in CED-3 activation and apoptosis", Science, 1998, pp. 1355-1357, Vol. 281	
	A74	JIAN YU et al., "PUMA induces the rapid apoptosis of colorectal cancer cells", Molecular Cell, 2001, pp. 673-682, Vol. 7	
	A75	WEI-XING ZONG et al., "BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak", Genes & Development, 2001, pp. 1481-1486, Vol. 15	
	A76	HUA ZOU et al., Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of Caspase-3", Cell, 1997, pp. 405-413, Vol. 90	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.